title: Abnormal glutathione conjugation in patients with tyrosinaemia type I.
abstract: Previous studies have suggested that tyrosinaemia type I may be associated with reduced glutathione availability due to conjugation of tyrosinaemia-associated reactive intermediates with glutathione. In the present study, the glutathione/ glutathione S-transferase system of two tyrosinaemia patients and three healthy controls were characterized by administering the racemic sedative drug bromisoval, a probe drug for assessing glutathione conjugation activity in vivo. Furthermore, concentrations of glutathione and glutathione S-transferase class alpha (GSTA) isoenzymes as well as the glutathione S-transferase class mu phenotype were assessed in the blood of six tyrosinaemia patients. The excretion of bromisoval mercapturates in healthy children was comparable to that observed in healthy adults. Tyrosinaemia patients were found to have a very high urinary recovery of bromisoval mercapturates (> or = 60% of the dose compared to about 30% for healthy, age-matched children and adults), which could be attributed mainly to a higher urinary excretion of the mercapturate derived from S-bromisoval. Healthy children and adults predominantly excrete the (R)-bromisoval mercapturate. The differences in amount excreted as well as in stereoselectivity of the urinary excretion of bromisoval mercapturates in tyrosinaemia patients are possibly related to an increased activity of specific glutathione S-transferase isoenzymes. Plasma glutathione and blood cell glutathione disulphide concentrations in tyrosinaemia patients were normal. Low blood cell glutathione concentrations were in general found only in two patients with a poor clinical condition. These results indicate that, in contrast to previous suggestions, reduced glutathione availability is not a generalized problem in (stabilized) tyrosinaemia patients.
authors.affiliation: Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands.
authors.forename: T M
authors.initials: TM
authors.lastname: Mulders
authors.forename: D J
authors.initials: DJ
authors.lastname: Bergman
authors.forename: B T
authors.initials: BT
authors.lastname: Poll-The
authors.forename: G P
authors.initials: GP
authors.lastname: Smit
authors.forename: D D
authors.initials: DD
authors.lastname: Breimer
authors.forename: G J
authors.initials: GJ
authors.lastname: Mulder
authors.forename: M
authors.initials: M
authors.lastname: Duran
authors.forename: J A
authors.initials: JA
authors.lastname: Smeitink
mesh_terms: D000328:Adult; D000592:Amino Acid Metabolism, Inborn Errors / Q000201:enzymology / Q000235:genetics / Q000378:metabolism*; D001968:Bromisovalum / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005978:Glutathione / Q000378:metabolism*; D005982:Glutathione Transferase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006993:Hypnotics and Sedatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D007223:Infant; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D008297:Male; D010641:Phenotype; D011110:Polymorphism, Genetic; D012016:Reference Values; D013237:Stereoisomerism; D014443:Tyrosine / Q000378:metabolism*
chemical_list: D006993:Hypnotics and Sedatives; D007527:Isoenzymes; D014443:Tyrosine; D001968:Bromisovalum; D005982:Glutathione Transferase; D005978:Glutathione